Compare NXL & COSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXL | COSM |
|---|---|---|
| Founded | 2010 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6M | 18.9M |
| IPO Year | 2022 | 2013 |
| Metric | NXL | COSM |
|---|---|---|
| Price | $0.61 | $0.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 156.8K | ★ 1.3M |
| Earning Date | 03-13-2026 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $156,931.00 | ★ $59,792,819.00 |
| Revenue This Year | $38.28 | $20.69 |
| Revenue Next Year | $185.71 | $53.10 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.69 |
| 52 Week Low | $0.54 | $0.28 |
| 52 Week High | $3.87 | $1.32 |
| Indicator | NXL | COSM |
|---|---|---|
| Relative Strength Index (RSI) | 35.08 | 46.18 |
| Support Level | $0.58 | $0.47 |
| Resistance Level | $0.77 | $0.59 |
| Average True Range (ATR) | 0.05 | 0.06 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 9.09 | 45.63 |
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.